Atara, Pierre Fabre seek FDA meeting on EBVALLO

Atara Biotherapeutics ( (ATRA) ) just unveiled an announcement.

On March 3, 2026, Atara Biotherapeutics reported that its partner Pierre Fabre Pharmaceuticals has requested a Type A meeting with the U.S. Food and Drug Administration to address issues raised in the Complete Response Letter issued on January 9, 2026, for the Biologics License Application for EBVALLO (tabelecleucel). The partners have submitted a briefing package arguing that the ALLELE study was adequate and well-controlled, supplemented by updated longer-term efficacy data, additional development data, and European post-marketing experience, underscoring the urgent need for tabelecleucel in patients with ultra-rare EBV-positive post-transplant lymphoproliferative disease and the potential path to revive U.S. approval prospects.

The most recent analyst rating on (ATRA) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Atara Biotherapeutics stock, see the ATRA Stock Forecast page.

Spark’s Take on ATRA Stock

According to Spark, TipRanks’ AI Analyst, ATRA is a Neutral.

The score is primarily held down by weak financial performance (negative equity and ongoing cash burn) and very bearish technicals (price far below key moving averages with negative MACD). A highly negative corporate event (FDA CRL for EBVALLO) further increases risk, while the low P/E provides only partial support given the underlying uncertainty.

To see Spark’s full report on ATRA stock, click here.

More about Atara Biotherapeutics

Atara Biotherapeutics, Inc. is a Southern California–based biotechnology company specializing in off-the-shelf allogeneic T-cell immunotherapies for difficult-to-treat cancers and autoimmune conditions. Leveraging an Epstein-Barr virus–targeted T-cell platform that avoids T-cell receptor and HLA gene editing, it has built a diverse portfolio of investigational therapies and was the first company to secure regulatory approval for an allogeneic T-cell therapy.

Average Trading Volume: 320,360

Technical Sentiment Signal: Strong Sell

Current Market Cap: $35.4M

For detailed information about ATRA stock, go to TipRanks’ Stock Analysis page.